Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression
Skp2 E3 ligase is overexpressed in numerous human cancers and plays a critical role in cell-cycle progression, senescence, metabolism, cancer progression, and metastasis. In the present study, we identified a specific Skp2 inhibitor using high-throughput in silico screening of large and diverse chem...
Saved in:
Published in | Cell Vol. 154; no. 3; pp. 556 - 568 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.08.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Skp2 E3 ligase is overexpressed in numerous human cancers and plays a critical role in cell-cycle progression, senescence, metabolism, cancer progression, and metastasis. In the present study, we identified a specific Skp2 inhibitor using high-throughput in silico screening of large and diverse chemical libraries. This Skp2 inhibitor selectively suppresses Skp2 E3 ligase activity, but not activity of other SCF complexes. It also phenocopies the effects observed upon genetic Skp2 deficiency, such as suppressing survival and Akt-mediated glycolysis and triggering p53-independent cellular senescence. Strikingly, we discovered a critical function of Skp2 in positively regulating cancer stem cell populations and self-renewal ability through genetic and pharmacological approaches. Notably, Skp2 inhibitor exhibits potent antitumor activities in multiple animal models and cooperates with chemotherapeutic agents to reduce cancer cell survival. Our study thus provides pharmacological evidence that Skp2 is a promising target for restricting cancer stem cell and cancer progression.
[Display omitted]
•Integrated computational approaches identify a specific Skp2 inhibitor•The Skp2 inhibitor selectively impairs Skp2 activity and functions•Skp2 inactivation restricts cancer stemness and potentiates chemotherapy sensitivity•The Skp2 inhibitor exhibits potent antitumor activity
A selective Skp2 inhibitor identified through a virtual chemical screen suppresses cancer stem cell renewal and cancer progression, establishing Skp2 as a promising target for cancer treatment. |
---|---|
AbstractList | Skp2 E3 ligase is overexpressed in numerous human cancers and plays a critical role in cell-cycle progression, senescence, metabolism, cancer progression, and metastasis. In the present study, we identified a specific Skp2 inhibitor using high-throughput in silico screening of large and diverse chemical libraries. This Skp2 inhibitor selectively suppresses Skp2 E3 ligase activity, but not activity of other SCF complexes. It also phenocopies the effects observed upon genetic Skp2 deficiency, such as suppressing survival and Akt-mediated glycolysis and triggering p53-independent cellular senescence. Strikingly, we discovered a critical function of Skp2 in positively regulating cancer stem cell populations and self-renewal ability through genetic and pharmacological approaches. Notably, Skp2 inhibitor exhibits potent antitumor activities in multiple animal models and cooperates with chemotherapeutic agents to reduce cancer cell survival. Our study thus provides pharmacological evidence that Skp2 is a promising target for restricting cancer stem cell and cancer progression. Skp2 E3 ligase is overexpressed in numerous human cancers and plays a critical role in cell cycle progression, senescence, metabolism, cancer progression and metastasis. In the present study, we identified a specific Skp2 inhibitor using high-throughput in silico screening of large and diverse chemical libraries. This Skp2 inhibitor selectively suppresses Skp2 E3 ligase activity, but not activity of other SCF complexes. It also phenocopies the effects observed upon genetic Skp2 deficiency, such as suppressing survival, Akt-mediated glycolysis as well as triggering p53-independent cellular senescence. Strikingly, we discovered a critical function of Skp2 in positively regulating cancer stem cell populations and self-renewal ability through genetic and pharmacological approaches. Notably, Skp2 inhibitor exhibits potent anti-tumor activities in multiple animal models and cooperates with chemotherapeutic agents to reduce cancer cell survival. Our study thus provides pharmacological evidence that Skp2 is a promising target for restricting cancer stem cell and cancer progression. Skp2 E3 ligase is overexpressed in numerous human cancers and plays a critical role in cell-cycle progression, senescence, metabolism, cancer progression, and metastasis. In the present study, we identified a specific Skp2 inhibitor using high-throughput in silico screening of large and diverse chemical libraries. This Skp2 inhibitor selectively suppresses Skp2 E3 ligase activity, but not activity of other SCF complexes. It also phenocopies the effects observed upon genetic Skp2 deficiency, such as suppressing survival and Akt-mediated glycolysis and triggering p53-independent cellular senescence. Strikingly, we discovered a critical function of Skp2 in positively regulating cancer stem cell populations and self-renewal ability through genetic and pharmacological approaches. Notably, Skp2 inhibitor exhibits potent antitumor activities in multiple animal models and cooperates with chemotherapeutic agents to reduce cancer cell survival. Our study thus provides pharmacological evidence that Skp2 is a promising target for restricting cancer stem cell and cancer progression. [Display omitted] •Integrated computational approaches identify a specific Skp2 inhibitor•The Skp2 inhibitor selectively impairs Skp2 activity and functions•Skp2 inactivation restricts cancer stemness and potentiates chemotherapy sensitivity•The Skp2 inhibitor exhibits potent antitumor activity A selective Skp2 inhibitor identified through a virtual chemical screen suppresses cancer stem cell renewal and cancer progression, establishing Skp2 as a promising target for cancer treatment. |
Author | Lin, Hui-Kuan Xu, Dazhi Hung, Mien-Chie Chan, Chia-Hsin Ladbury, John E. Zhang, Shuxing Stagg, Loren J. Gao, Yuan Li, Chien-Feng Logothetis, Christopher J. Morrow, John Kenneth Jin, Guoxiang Cai, Zhen Moten, Asad |
AuthorAffiliation | 7 Department of Biochemistry and Molecular Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA 8 Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA 1 Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA 6 Faculty of Arts and Sciences, Harvard University, Cambridge, MA 02138, USA 4 Department of Pathology, Chi-Mei Foundational Medical Center, Tainan 710, Taiwan 9 Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University, Taichung 404, Taiwan 5 National Institute of Cancer Research, National Health Research Institutes, Tainan 704, Taiwan 3 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA 2 The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA |
AuthorAffiliation_xml | – name: 3 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA – name: 9 Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University, Taichung 404, Taiwan – name: 2 The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA – name: 7 Department of Biochemistry and Molecular Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA – name: 5 National Institute of Cancer Research, National Health Research Institutes, Tainan 704, Taiwan – name: 6 Faculty of Arts and Sciences, Harvard University, Cambridge, MA 02138, USA – name: 8 Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA – name: 4 Department of Pathology, Chi-Mei Foundational Medical Center, Tainan 710, Taiwan – name: 1 Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA |
Author_xml | – sequence: 1 givenname: Chia-Hsin surname: Chan fullname: Chan, Chia-Hsin organization: Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA – sequence: 2 givenname: John Kenneth surname: Morrow fullname: Morrow, John Kenneth organization: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA – sequence: 3 givenname: Chien-Feng surname: Li fullname: Li, Chien-Feng organization: Department of Pathology, Chi-Mei Foundational Medical Center, Tainan 710, Taiwan – sequence: 4 givenname: Yuan surname: Gao fullname: Gao, Yuan organization: Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA – sequence: 5 givenname: Guoxiang surname: Jin fullname: Jin, Guoxiang organization: Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA – sequence: 6 givenname: Asad surname: Moten fullname: Moten, Asad organization: Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA – sequence: 7 givenname: Loren J. surname: Stagg fullname: Stagg, Loren J. organization: Department of Biochemistry and Molecular Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA – sequence: 8 givenname: John E. surname: Ladbury fullname: Ladbury, John E. organization: Department of Biochemistry and Molecular Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA – sequence: 9 givenname: Zhen surname: Cai fullname: Cai, Zhen organization: Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA – sequence: 10 givenname: Dazhi surname: Xu fullname: Xu, Dazhi organization: Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA – sequence: 11 givenname: Christopher J. surname: Logothetis fullname: Logothetis, Christopher J. organization: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA – sequence: 12 givenname: Mien-Chie surname: Hung fullname: Hung, Mien-Chie organization: Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA – sequence: 13 givenname: Shuxing surname: Zhang fullname: Zhang, Shuxing email: shuzhang@mdanderson.org organization: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA – sequence: 14 givenname: Hui-Kuan surname: Lin fullname: Lin, Hui-Kuan email: hklin@mdanderson.org organization: Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23911321$$D View this record in MEDLINE/PubMed |
BookMark | eNp9UU1r3DAUFCWl2aT9Az20OvZiV1-2ZSiFYpo0sNDQzZ7Fsyw72trSRvIu9N9HZpPQXnoSvDczmjdzgc6cdwah95TklNDy8y7XZhxzRijPSZkTIV-hFSV1lQlasTO0IqRmmSwrcY4uYtwRQmRRFG_QOeM1pZzRFQq39xAm0H70g9Uw4hsHerZHmK132Pd483vP8Ka5wtvWPhzsbB1e2wGiwb9MnIPVc8QNOG0C3sxmwk2yhO8C2DQH1z3vboMfgokxqb5Fr3sYo3n39F6i7dX3u-ZHtv55fdN8W2daVMWcSd5yLqTkJWjRtqSrOiZ0BUzKqhKkpqJqTc-AEQlEljXIjvUFLYmkLRjO-SX6etLdH9rJdNq4OcCo9sFOEP4oD1b9u3H2Xg3-qLgUhShYEvj0JBD8wyFdqyYbl8jBGX-IigoqqZAp5QRlJ6gOPsZg-pdvKFFLWWqnFqZaylKkVKmsRPrwt8EXynM7CfDxBOjBKxiCjWq7SQplapIxIpYbv5wQJgV5tCaoqK1JiXc2GD2rztv_OXgE0GuxfQ |
CitedBy_id | crossref_primary_10_1002_med_21675 crossref_primary_10_1016_j_semcancer_2024_05_002 crossref_primary_10_1158_0008_5472_CAN_19_1269 crossref_primary_10_3390_cancers12061579 crossref_primary_10_15252_embj_201696089 crossref_primary_10_1093_abbs_gmaa053 crossref_primary_10_1007_s13402_023_00777_x crossref_primary_10_1111_cas_14240 crossref_primary_10_1007_s13577_020_00427_6 crossref_primary_10_1016_j_bbcan_2014_11_005 crossref_primary_10_1186_s12943_017_0649_0 crossref_primary_10_1038_s41598_022_06451_w crossref_primary_10_1021_acs_jmedchem_2c01675 crossref_primary_10_1080_10428194_2017_1359740 crossref_primary_10_1016_j_ebiom_2021_103756 crossref_primary_10_1371_journal_pone_0086238 crossref_primary_10_1021_acs_jmedchem_9b01451 crossref_primary_10_1038_leu_2014_255 crossref_primary_10_18632_oncotarget_3394 crossref_primary_10_1146_annurev_cancerbio_030617_050430 crossref_primary_10_1016_j_molcel_2015_01_015 crossref_primary_10_1182_blood_2013_04_497040 crossref_primary_10_1016_j_str_2018_06_004 crossref_primary_10_1038_ncomms11702 crossref_primary_10_1038_s41467_018_05177_6 crossref_primary_10_1038_nrc3622 crossref_primary_10_1371_journal_pone_0134896 crossref_primary_10_1128_MCB_01506_13 crossref_primary_10_3390_cancers12061595 crossref_primary_10_15252_embj_201694795 crossref_primary_10_1186_s43556_021_00043_2 crossref_primary_10_1084_jem_20171312 crossref_primary_10_1038_s41388_019_0955_7 crossref_primary_10_3389_fmolb_2018_00019 crossref_primary_10_5812_ircmj_28947 crossref_primary_10_3748_wjg_v29_i45_5974 crossref_primary_10_1007_s00109_022_02229_9 crossref_primary_10_1016_j_phrs_2022_106059 crossref_primary_10_1007_s00277_023_05415_y crossref_primary_10_1038_onc_2016_175 crossref_primary_10_1002_ijc_31040 crossref_primary_10_3389_fonc_2020_574011 crossref_primary_10_1038_s41388_017_0118_7 crossref_primary_10_3389_fonc_2024_1288501 crossref_primary_10_1186_1476_4598_13_260 crossref_primary_10_1038_bjc_2014_136 crossref_primary_10_1038_nrd_2016_211 crossref_primary_10_3892_or_2016_4809 crossref_primary_10_1038_s41580_021_00448_5 crossref_primary_10_3390_ijms232315104 crossref_primary_10_18632_oncotarget_11614 crossref_primary_10_3892_ol_2015_3172 crossref_primary_10_1071_CH14586 crossref_primary_10_1186_s12935_020_01683_0 crossref_primary_10_1016_j_molcel_2015_05_010 crossref_primary_10_1158_1078_0432_CCR_13_1942 crossref_primary_10_3390_ijms21062041 crossref_primary_10_1080_13543776_2018_1549229 crossref_primary_10_1142_S0192415X23500349 crossref_primary_10_1021_acs_bioconjchem_9b00628 crossref_primary_10_1016_j_bbrc_2018_09_059 crossref_primary_10_1038_s41392_020_00315_3 crossref_primary_10_1007_s10593_023_03216_9 crossref_primary_10_1038_s41467_021_23816_3 crossref_primary_10_3389_fcell_2021_665646 crossref_primary_10_3390_cancers13123079 crossref_primary_10_1002_ange_201307761 crossref_primary_10_1038_ncomms7641 crossref_primary_10_1042_BJ20141450 crossref_primary_10_1002_jcp_30466 crossref_primary_10_1016_j_blre_2013_10_002 crossref_primary_10_1007_s11926_021_01022_w crossref_primary_10_1080_15384101_2017_1346760 crossref_primary_10_3390_ijms20112667 crossref_primary_10_1093_jnci_dju083 crossref_primary_10_1039_C8MD00140E crossref_primary_10_1016_j_ccr_2013_09_021 crossref_primary_10_1038_s41419_021_03555_5 crossref_primary_10_1038_nrc3594 crossref_primary_10_1093_nar_gkaa1002 crossref_primary_10_1155_2020_8072639 crossref_primary_10_1016_j_lfs_2023_122333 crossref_primary_10_1007_s00432_024_05659_9 crossref_primary_10_1021_acs_jmedchem_6b01817 crossref_primary_10_1016_j_trecan_2021_08_002 crossref_primary_10_1002_btm2_10044 crossref_primary_10_1038_bjc_2014_594 crossref_primary_10_1038_cddis_2014_66 crossref_primary_10_1158_1078_0432_CCR_14_2785 crossref_primary_10_1002_bies_202100057 crossref_primary_10_1210_en_2013_1873 crossref_primary_10_1098_rsob_200390 crossref_primary_10_1038_cddis_2014_501 crossref_primary_10_4161_cc_27853 crossref_primary_10_1016_j_drudis_2021_07_006 crossref_primary_10_1111_cas_15005 crossref_primary_10_1002_chem_201705983 crossref_primary_10_7314_APJCP_2015_16_9_3805 crossref_primary_10_1021_acs_jnatprod_5b00743 crossref_primary_10_3389_fonc_2021_679445 crossref_primary_10_1002_cbic_202100504 crossref_primary_10_1210_en_2013_1757 crossref_primary_10_3892_ijo_2018_4345 crossref_primary_10_1016_j_isci_2024_109246 crossref_primary_10_18632_oncotarget_2431 crossref_primary_10_3390_cancers14122855 crossref_primary_10_3390_cells10123309 crossref_primary_10_1038_nrc3700 crossref_primary_10_3390_ijms24032809 crossref_primary_10_1016_j_ebiom_2019_11_031 crossref_primary_10_3390_ijms21186885 crossref_primary_10_1038_s41467_018_07188_9 crossref_primary_10_1007_s12272_020_01281_8 crossref_primary_10_1038_onc_2015_2 crossref_primary_10_3390_ijms22041784 crossref_primary_10_1016_j_molcel_2016_08_009 crossref_primary_10_1007_s12035_021_02339_4 crossref_primary_10_1002_anie_201307761 crossref_primary_10_1080_19768354_2016_1213768 crossref_primary_10_1016_j_semcancer_2015_09_008 crossref_primary_10_1158_0008_5472_CAN_19_3116 crossref_primary_10_1016_j_scib_2023_04_028 crossref_primary_10_1038_s41419_024_06629_2 crossref_primary_10_1371_journal_pgen_1009354 crossref_primary_10_1016_j_semcancer_2015_09_015 crossref_primary_10_1016_j_semcdb_2022_02_007 crossref_primary_10_1038_s41419_022_04685_0 crossref_primary_10_1016_j_semcancer_2015_09_014 crossref_primary_10_7554_eLife_35136 crossref_primary_10_15212_AMM_2022_0011 crossref_primary_10_1038_nrd4130 crossref_primary_10_1002_ijc_28804 crossref_primary_10_18632_oncotarget_13153 crossref_primary_10_4143_crt_2016_017 crossref_primary_10_1016_j_tcb_2014_02_001 crossref_primary_10_3390_cancers12071898 crossref_primary_10_18632_oncotarget_6934 crossref_primary_10_1038_s41392_021_00500_y crossref_primary_10_3390_cancers13040683 crossref_primary_10_1002_1878_0261_13497 crossref_primary_10_1084_jem_20222056 crossref_primary_10_1038_s42003_023_05166_6 crossref_primary_10_1016_j_ccell_2016_08_003 crossref_primary_10_1371_journal_pcbi_1004021 crossref_primary_10_1016_j_celrep_2018_03_047 crossref_primary_10_1016_j_molcel_2021_04_023 crossref_primary_10_1016_j_molcel_2018_08_029 crossref_primary_10_1074_jbc_M114_629931 crossref_primary_10_3390_cancers12051249 crossref_primary_10_1002_jcb_24704 crossref_primary_10_3389_fmolb_2022_844129 crossref_primary_10_3390_ijms22062844 crossref_primary_10_1158_0008_5472_CAN_19_2400 crossref_primary_10_3390_ijms24098441 crossref_primary_10_1016_j_phymed_2023_154856 crossref_primary_10_1186_s40169_018_0205_6 crossref_primary_10_1038_onc_2013_445 crossref_primary_10_1016_j_bmc_2016_03_023 crossref_primary_10_1002_ctm2_1204 crossref_primary_10_1080_15384101_2015_1120916 crossref_primary_10_1002_jcp_24545 crossref_primary_10_1038_s41467_024_48184_6 crossref_primary_10_1016_j_biocel_2017_06_011 crossref_primary_10_7554_eLife_68136 crossref_primary_10_1016_j_compbiolchem_2019_02_003 crossref_primary_10_1186_s12935_014_0126_4 crossref_primary_10_1186_s13287_019_1222_0 crossref_primary_10_1038_onc_2014_399 crossref_primary_10_1002_iub_2460 crossref_primary_10_1016_j_bbcan_2016_05_001 crossref_primary_10_1038_onc_2016_300 crossref_primary_10_1080_15384101_2017_1327490 crossref_primary_10_3390_cancers15041040 crossref_primary_10_1097_FBP_0000000000000773 crossref_primary_10_1016_j_omto_2019_01_006 crossref_primary_10_3390_cancers12123764 crossref_primary_10_1186_2045_3701_4_59 crossref_primary_10_1080_15384101_2016_1157238 crossref_primary_10_3390_ph16121649 crossref_primary_10_1007_s10555_017_9703_z crossref_primary_10_1080_15384101_2017_1288326 crossref_primary_10_1042_BST20150103 crossref_primary_10_1111_cpr_12191 crossref_primary_10_3390_ijms19020474 crossref_primary_10_18632_oncotarget_4090 crossref_primary_10_1038_s41392_020_00418_x crossref_primary_10_1080_23723556_2016_1242454 crossref_primary_10_1016_j_tips_2014_01_005 crossref_primary_10_1016_j_celrep_2022_110301 crossref_primary_10_1128_JVI_00155_14 crossref_primary_10_3389_fphar_2024_1400029 crossref_primary_10_1038_nrdp_2015_21 crossref_primary_10_18632_oncotarget_14041 crossref_primary_10_1002_ange_201508716 crossref_primary_10_1111_nyas_14578 crossref_primary_10_1002_mnfr_202300061 crossref_primary_10_1007_s12253_016_0049_6 crossref_primary_10_3390_ph6111361 crossref_primary_10_1002_cnr2_1369 crossref_primary_10_1038_leu_2016_258 crossref_primary_10_1016_j_yexcr_2020_112335 crossref_primary_10_1038_s41375_019_0653_z crossref_primary_10_1007_s12013_023_01160_1 crossref_primary_10_1016_j_phrs_2016_05_027 crossref_primary_10_3390_cancers13092235 crossref_primary_10_1002_advs_201900949 crossref_primary_10_1126_scisignal_aao3810 crossref_primary_10_4143_crt_2021_373 crossref_primary_10_3389_fcell_2022_944460 crossref_primary_10_3892_mmr_2016_5676 crossref_primary_10_4155_fmc_2017_0009 crossref_primary_10_1186_s12929_022_00860_9 crossref_primary_10_1002_anie_201508716 crossref_primary_10_1186_s12885_015_1265_2 crossref_primary_10_1186_s12929_018_0470_0 crossref_primary_10_3389_fonc_2020_621294 crossref_primary_10_1021_acs_jcim_2c00920 crossref_primary_10_3892_etm_2017_5489 crossref_primary_10_1038_oncsis_2014_14 crossref_primary_10_1146_annurev_biochem_060815_014922 crossref_primary_10_1016_j_canlet_2017_07_030 crossref_primary_10_1158_1535_7163_MCT_23_0173 crossref_primary_10_1038_s41392_020_0107_0 crossref_primary_10_18632_aging_204650 crossref_primary_10_1016_j_ygeno_2020_04_029 crossref_primary_10_1016_j_jbiosc_2014_06_009 crossref_primary_10_1158_1078_0432_CCR_15_2208 crossref_primary_10_1016_j_apsb_2020_12_015 crossref_primary_10_18632_genesandcancer_151 crossref_primary_10_1038_s41419_020_02755_9 crossref_primary_10_18632_oncotarget_2149 crossref_primary_10_1038_nrc_2017_105 crossref_primary_10_3390_ijms23010514 crossref_primary_10_1186_s13046_022_02284_7 crossref_primary_10_1016_j_prp_2024_155443 crossref_primary_10_1186_s12935_020_1144_z crossref_primary_10_2139_ssrn_4123505 crossref_primary_10_1038_s41467_023_44130_0 crossref_primary_10_1038_nrd4432 crossref_primary_10_1158_0008_5472_CAN_17_1965 crossref_primary_10_1016_j_apsb_2019_09_005 crossref_primary_10_1038_onc_2017_64 crossref_primary_10_1016_j_chembiol_2021_04_008 crossref_primary_10_1016_j_neo_2015_08_008 crossref_primary_10_1038_cr_2016_31 crossref_primary_10_1111_cas_12958 crossref_primary_10_1016_j_bmc_2021_116423 crossref_primary_10_18632_oncotarget_5547 crossref_primary_10_1155_2022_8723725 crossref_primary_10_1002_cmdc_201700359 crossref_primary_10_1038_s41418_020_00648_0 crossref_primary_10_1073_pnas_1522367113 crossref_primary_10_3892_ijo_2015_2983 crossref_primary_10_1016_j_lfs_2022_121135 crossref_primary_10_3390_ph17030326 crossref_primary_10_1172_jci_insight_88427 crossref_primary_10_1038_s41388_024_02942_4 crossref_primary_10_1002_embr_201338373 crossref_primary_10_1371_journal_pone_0150336 crossref_primary_10_1146_annurev_cancerbio_040716_075607 crossref_primary_10_1016_j_ejphar_2023_175697 crossref_primary_10_18632_oncotarget_10057 crossref_primary_10_1016_j_biocel_2018_06_001 crossref_primary_10_1007_s12032_015_0619_6 crossref_primary_10_1016_j_phrs_2022_106259 crossref_primary_10_1038_s41388_020_01423_8 crossref_primary_10_18632_oncotarget_2945 crossref_primary_10_1016_j_ebiom_2019_12_002 crossref_primary_10_1128_MCB_01461_14 crossref_primary_10_1371_journal_pone_0079201 crossref_primary_10_1038_s41419_020_02881_4 crossref_primary_10_1038_onc_2014_364 crossref_primary_10_1038_nrc3773 crossref_primary_10_1038_s41388_024_02977_7 crossref_primary_10_1186_s13073_022_01068_0 crossref_primary_10_3389_fphar_2023_1122008 crossref_primary_10_1007_s11626_021_00545_x crossref_primary_10_1038_aja_2013_115 crossref_primary_10_1042_BSR20160152 crossref_primary_10_1016_j_semcancer_2020_01_013 crossref_primary_10_3389_fphar_2022_768556 crossref_primary_10_4161_15384101_2014_972901 crossref_primary_10_18632_oncotarget_9236 crossref_primary_10_4137_BCBCR_S30101 crossref_primary_10_1039_D2CB00201A crossref_primary_10_1038_s41388_022_02559_5 crossref_primary_10_3390_ijms22020476 crossref_primary_10_3390_ijms15058169 crossref_primary_10_1016_j_ijrobp_2015_08_046 crossref_primary_10_1002_jso_23764 crossref_primary_10_3390_ijms21176335 crossref_primary_10_1002_1878_0261_13312 crossref_primary_10_1038_s41421_019_0092_z crossref_primary_10_4155_fmc_15_148 crossref_primary_10_1016_j_bbcan_2023_189035 crossref_primary_10_1016_j_apsb_2023_07_019 |
Cites_doi | 10.1016/j.bmc.2011.01.049 10.1074/jbc.M608144200 10.1038/nature08815 10.1074/jbc.M111.274613 10.1126/science.1175065 10.1016/S1097-2765(03)00193-X 10.1504/IJBRA.2009.026419 10.1016/j.cell.2011.11.050 10.1100/tsw.2010.89 10.1038/35042620 10.1007/s10822-007-9102-6 10.1038/nrc2396 10.1038/ncb2047 10.1182/blood-2007-09-112904 10.1126/science.1160809 10.1016/S1097-2765(03)00173-4 10.1038/nature07884 10.1093/nar/gkq323 10.1016/S1534-5807(04)00131-5 10.1038/ng.498 10.1038/12013 10.1038/ncb1849 10.1016/j.chembiol.2012.09.015 10.1016/j.cell.2012.02.065 10.1016/j.molcel.2005.09.003 10.1007/s12015-008-9037-x 10.1038/416703a 10.1074/jbc.M301774200 10.1007/s00109-011-0766-y 10.1158/1078-0432.CCR-09-2850 10.1093/bioinformatics/btp036 10.1038/nrd2656 10.1158/0008-5472.CAN-03-2904 10.1016/j.semcancer.2008.11.010 10.1007/978-1-61779-012-6_2 10.1002/cncr.23317 10.1111/j.1349-7006.2003.tb01444.x 10.1021/ci2001742 10.1016/S0076-6879(05)98012-9 10.1016/j.bmc.2009.08.022 10.1016/j.semcancer.2010.02.003 |
ContentType | Journal Article |
Copyright | 2013 Elsevier Inc. Copyright © 2013 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2013 Elsevier Inc. – notice: Copyright © 2013 Elsevier Inc. All rights reserved. |
DBID | 6I. AAFTH FBQ CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1016/j.cell.2013.06.048 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access AGRIS Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1097-4172 |
EndPage | 568 |
ExternalDocumentID | 10_1016_j_cell_2013_06_048 23911321 US201600022043 S0092867413008301 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIGMS NIH HHS grantid: P41 GM079588 – fundername: NCI NIH HHS grantid: P30 CA016672 – fundername: NCI NIH HHS grantid: R01 CA136787 – fundername: NCI NIH HHS grantid: P50 CA140388 – fundername: NCI NIH HHS grantid: CA016672 – fundername: NCI NIH HHS grantid: R01 CA149321 – fundername: National Cancer Institute : NCI grantid: P30 CA016672 || CA – fundername: National Cancer Institute : NCI grantid: P50 CA140388 || CA |
GroupedDBID | --- --K -DZ -ET -~X 0R~ 0WA 1RT 1~5 29B 2FS 2WC 3EH 4.4 457 4G. 53G 5GY 5RE 5VS 62- 6I. 6J9 7-5 85S AACTN AAEDT AAEDW AAFTH AAFWJ AAIAV AAIKJ AAKRW AAKUH AAQFI AAUCE AAVLU AAXJY AAXUO AAYJJ ABCQX ABJNI ABMAC ABMWF ABOCM ABVKL ACGFO ACGFS ACNCT ADBBV ADEZE ADJPV AEFWE AENEX AEXQZ AFDAS AFTJW AGHFR AGHSJ AGKMS AHHHB AIDAL AITUG ALKID ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN BAWUL CS3 DIK DU5 E3Z EBS EJD F5P FCP FDB FIRID HH5 IH2 IHE IXB J1W JIG K-O KOO KQ8 L7B LX5 M3Z M41 N9A NCXOZ O-L O9- OK1 P2P RCE RIG RNS ROL RPZ SCP SDG SDP SES SSZ TAE TN5 TR2 TWZ UKR UPT VQA WH7 WQ6 YYQ YZZ ZA5 ZCA .-4 .55 .GJ .HR 1CY 1VV 2KS 3O- 6TJ 9M8 AALRI AAQXK ABEFU ABPTK ABTAH ADMUD AEQTP AETEA AI. FBQ FEDTE FGOYB G-2 G8K HVGLF HZ~ H~9 MVM OHT OMK OZT PUQ R2- UBW UHB VH1 X7M XFK YYP ZGI ZHY ZKB ZY4 0SF AAHBH AAMRU ADVLN AKAPO AKRWK CGR CUY CVF ECM EIF NPM AAYXX ABDPE ACRPL ADNMO CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c475t-83b3348836ac4bb0d7d24c7a28877409147bef2a208a0869a8d2f516081bae333 |
IEDL.DBID | ABVKL |
ISSN | 0092-8674 |
IngestDate | Tue Sep 17 21:24:52 EDT 2024 Fri Oct 25 06:23:05 EDT 2024 Fri Dec 06 02:39:17 EST 2024 Sat Sep 28 07:54:50 EDT 2024 Wed Dec 27 19:22:01 EST 2023 Fri Feb 23 02:30:32 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
License | http://www.elsevier.com/open-access/userlicense/1.0 Copyright © 2013 Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c475t-83b3348836ac4bb0d7d24c7a28877409147bef2a208a0869a8d2f516081bae333 |
Notes | http://dx.doi.org/10.1016/j.cell.2013.06.048 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0092867413008301 |
PMID | 23911321 |
PQID | 1418148009 |
PQPubID | 23479 |
PageCount | 13 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3845452 proquest_miscellaneous_1418148009 crossref_primary_10_1016_j_cell_2013_06_048 pubmed_primary_23911321 fao_agris_US201600022043 elsevier_sciencedirect_doi_10_1016_j_cell_2013_06_048 |
PublicationCentury | 2000 |
PublicationDate | 2013-08-01 |
PublicationDateYYYYMMDD | 2013-08-01 |
PublicationDate_xml | – month: 08 year: 2013 text: 2013-08-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Cell |
PublicationTitleAlternate | Cell |
PublicationYear | 2013 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Zhang, Shyh-Chang, Yang, Rai, Umashankar, Ma, Soh, Sun, Tai, Nga (bib37) 2012; 148 Chan, Li, Yang, Gao, Lee, Feng, Huang, Tsai, Flores, Shao (bib7) 2012; 149 Lin, Wang, Chen, Teruya-Feldstein, Liu, Chan, Yang, Erdjument-Bromage, Nakayama, Nimer (bib16) 2009; 11 Soucy, Smith, Milhollen, Berger, Gavin, Adhikari, Brownell, Burke, Cardin, Critchley (bib24) 2009; 458 Chan, Lee, Wang, Lin (bib5) 2010; 10 Chen, Xie, Kuhn, Voorhees, Lopez-Girona, Mendy, Corral, Krenitsky, Xu, Moutouh-de Parseval (bib8) 2008; 111 Zhang (bib33) 2011; 716 Carrano, Eytan, Hershko, Pagano (bib3) 1999; 1 Chan, Gao, Moten, Lin (bib6) 2011; 89 Robey, Hay (bib21) 2009; 19 Ahad, Zuohe, Du-Cuny, Moses, Zhou, Zhang, Powis, Meuillet, Mash (bib1) 2011; 19 Nakayama, Nagahama, Minamishima, Miyake, Ishida, Hatakeyama, Kitagawa, Iemura, Natsume, Nakayama (bib19) 2004; 6 Kim, Herbst, Tworkowski, Salghetti, Tansey (bib13) 2003; 11 Elstrom, Bauer, Buzzai, Karnauskas, Harris, Plas, Zhuang, Cinalli, Alavi, Rudin, Thompson (bib10) 2004; 64 Vander Heiden, Cantley, Thompson (bib25) 2009; 324 Wang, Bauzon, Ji, Xu, Sun, Locker, Sellers, Nakayama, Nakayama, Cobrinik, Zhu (bib28) 2010; 42 Rajan, Srinivasan (bib20) 2008; 4 Koch, Krause, Baumann (bib14) 2010; 20 von der Lehr, Johansson, Wu, Bahram, Castell, Cetinkaya, Hydbring, Weidung, Nakayama, Nakayama (bib27) 2003; 11 Lin, Chen, Wang, Nardella, Lee, Chan, Yang, Wang, Egia, Nakayama (bib17) 2010; 464 Bornstein, Bloom, Sitry-Shevah, Nakayama, Pagano, Hershko (bib2) 2003; 278 Chan, Lee, Li, Wang, Yang, Wu, Wu, Nakayama, Kang, Huang (bib4) 2010; 12 Wu, Grigoryan, Li, Hao, Pagano, Cardozo (bib29) 2012; 19 Du-Cuny, Song, Moses, Powis, Mash, Meuillet, Zhang (bib9) 2009; 17 Frescas, Pagano (bib11) 2008; 8 Li, Pavletich, Schulman, Zheng (bib15) 2005; 398 Schulman, Carrano, Jeffrey, Bowen, Kinnucan, Finnin, Elledge, Harper, Pagano, Pavletich (bib23) 2000; 408 Sakai, Sakaue, Nakamura, Okada, Matsuki, Watanabe, Hiramatsu, Nakayama, Nakayama, Kasuga (bib22) 2007; 282 Yokoi, Yasui, Iizasa, Takahashi, Fujisawa, Inazawa (bib32) 2003; 94 Zhang, Du-Cuny (bib34) 2009; 5 Hershko (bib12) 2008; 112 Zhang, Kumar, Jiang, Wallqvist, Reifman (bib36) 2008; 9 Zheng, Schulman, Song, Miller, Jeffrey, Wang, Chu, Koepp, Elledge, Pagano (bib38) 2002; 416 Yadav, Prasad, Gupta, Sung, Phatak, Zhang, Aggarwal (bib30) 2012; 287 Yang, Wang, Chan, Lee, Campos, Lamothe, Hur, Grabiner, Lin, Darnay, Lin (bib31) 2009; 325 Zhang, Wei, Bastow, Zheng, Brossi, Lee, Tropsha (bib35) 2007; 21 Marian, Cho, McEllin, Maher, Hatanpaa, Madden, Mickey, Wright, Shay, Bachoo (bib18) 2010; 16 Vazquez, Bond, Levine, Bond (bib26) 2008; 7 12769844 - Mol Cell. 2003 May;11(5):1189-200 16275325 - Methods Enzymol. 2005;398:125-42 24052048 - Nat Rev Drug Discov. 2013 Oct;12(10):740 24077600 - Asian J Androl. 2013 Nov;15(6):717-8 20526532 - ScientificWorldJournal. 2010;10:1001-15 20237562 - Nature. 2010 Mar 18;464(7287):374-9 22632973 - Cell. 2012 May 25;149(5):1098-111 18305219 - Blood. 2008 May 1;111(9):4690-9 19966802 - Nat Genet. 2010 Jan;42(1):83-8 18260093 - Cancer. 2008 Apr 1;112(7):1415-24 24526126 - Cell Cycle. 2014;13(5):679-80 19713527 - Science. 2009 Aug 28;325(5944):1134-8 22065587 - J Biol Chem. 2012 Jan 2;287(1):245-56 12504025 - Mol Cell. 2002 Dec;10(6):1511-8 20048334 - Clin Cancer Res. 2010 Jan 1;16(1):154-63 11099048 - Nature. 2000 Nov 16;408(6810):381-6 18663609 - Stem Cell Rev. 2008 Sep;4(3):211-6 21318898 - Methods Mol Biol. 2011;716:23-38 19360080 - Nature. 2009 Apr 9;458(7239):732-6 18500245 - Nat Rev Cancer. 2008 Jun;8(6):438-49 22225612 - Cell. 2012 Jan 20;148(1-2):259-72 15130491 - Dev Cell. 2004 May;6(5):661-72 21353784 - Bioorg Med Chem. 2011 Mar 15;19(6):2046-54 15172999 - Cancer Res. 2004 Jun 1;64(11):3892-9 17082193 - J Biol Chem. 2007 Jan 19;282(3):2038-46 12824902 - Cancer Sci. 2003 Apr;94(4):344-9 20383141 - Nat Cell Biol. 2010 May;12(5):457-67 21594579 - J Mol Med (Berl). 2011 Sep;89(9):857-67 12730199 - J Biol Chem. 2003 Jul 11;278(28):25752-7 17340042 - J Comput Aided Mol Des. 2007 Jan-Mar;21(1-3):97-112 19460998 - Science. 2009 May 22;324(5930):1029-33 11961546 - Nature. 2002 Apr 18;416(6882):703-9 19525200 - Int J Bioinform Res Appl. 2009;5(3):269-79 12769843 - Mol Cell. 2003 May;11(5):1177-88 10559916 - Nat Cell Biol. 1999 Aug;1(4):193-9 19270694 - Nat Cell Biol. 2009 Apr;11(4):420-32 19734051 - Bioorg Med Chem. 2009 Oct 1;17(19):6983-92 19043449 - Nat Rev Drug Discov. 2008 Dec;7(12):979-87 18304355 - BMC Bioinformatics. 2008;9:126 19130886 - Semin Cancer Biol. 2009 Feb;19(1):25-31 20219680 - Semin Cancer Biol. 2010 Apr;20(2):116-24 23261596 - Chem Biol. 2012 Dec 21;19(12):1515-24 Zhang (10.1016/j.cell.2013.06.048_bib36) 2008; 9 Chan (10.1016/j.cell.2013.06.048_bib5) 2010; 10 Ahad (10.1016/j.cell.2013.06.048_bib1) 2011; 19 Sakai (10.1016/j.cell.2013.06.048_bib22) 2007; 282 Elstrom (10.1016/j.cell.2013.06.048_bib10) 2004; 64 Nakayama (10.1016/j.cell.2013.06.048_bib19) 2004; 6 Du-Cuny (10.1016/j.cell.2013.06.048_bib9) 2009; 17 Soucy (10.1016/j.cell.2013.06.048_bib24) 2009; 458 Brenke (10.1016/j.cell.2013.06.048_bib39) 2009; 25 Yokoi (10.1016/j.cell.2013.06.048_bib32) 2003; 94 Hershko (10.1016/j.cell.2013.06.048_bib12) 2008; 112 Zhang (10.1016/j.cell.2013.06.048_bib33) 2011; 716 Chan (10.1016/j.cell.2013.06.048_bib6) 2011; 89 Kim (10.1016/j.cell.2013.06.048_bib13) 2003; 11 Yang (10.1016/j.cell.2013.06.048_bib31) 2009; 325 Schulman (10.1016/j.cell.2013.06.048_bib23) 2000; 408 Vazquez (10.1016/j.cell.2013.06.048_bib26) 2008; 7 Carrano (10.1016/j.cell.2013.06.048_bib3) 1999; 1 Lin (10.1016/j.cell.2013.06.048_bib17) 2010; 464 von der Lehr (10.1016/j.cell.2013.06.048_bib27) 2003; 11 Yadav (10.1016/j.cell.2013.06.048_bib30) 2012; 287 Tran (10.1016/j.cell.2013.06.048_bib41) 2011; 51 Chan (10.1016/j.cell.2013.06.048_bib7) 2012; 149 Koch (10.1016/j.cell.2013.06.048_bib14) 2010; 20 Wang (10.1016/j.cell.2013.06.048_bib28) 2010; 42 Chan (10.1016/j.cell.2013.06.048_bib4) 2010; 12 Zhang (10.1016/j.cell.2013.06.048_bib34) 2009; 5 Hao (10.1016/j.cell.2013.06.048_bib40) 2005; 20 Bornstein (10.1016/j.cell.2013.06.048_bib2) 2003; 278 Robey (10.1016/j.cell.2013.06.048_bib21) 2009; 19 Zhang (10.1016/j.cell.2013.06.048_bib37) 2012; 148 Zheng (10.1016/j.cell.2013.06.048_bib38) 2002; 416 Tuncbag (10.1016/j.cell.2013.06.048_bib42) 2010; 38 Rajan (10.1016/j.cell.2013.06.048_bib20) 2008; 4 Wu (10.1016/j.cell.2013.06.048_bib29) 2012; 19 Marian (10.1016/j.cell.2013.06.048_bib18) 2010; 16 Vander Heiden (10.1016/j.cell.2013.06.048_bib25) 2009; 324 Zhang (10.1016/j.cell.2013.06.048_bib35) 2007; 21 Chen (10.1016/j.cell.2013.06.048_bib8) 2008; 111 Frescas (10.1016/j.cell.2013.06.048_bib11) 2008; 8 Li (10.1016/j.cell.2013.06.048_bib15) 2005; 398 Lin (10.1016/j.cell.2013.06.048_bib16) 2009; 11 |
References_xml | – volume: 11 start-page: 1189 year: 2003 end-page: 1200 ident: bib27 article-title: The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription publication-title: Mol. Cell contributor: fullname: Nakayama – volume: 10 start-page: 1001 year: 2010 end-page: 1015 ident: bib5 article-title: Regulation of Skp2 expression and activity and its role in cancer progression publication-title: ScientificWorldJournal contributor: fullname: Lin – volume: 1 start-page: 193 year: 1999 end-page: 199 ident: bib3 article-title: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 publication-title: Nat. Cell Biol. contributor: fullname: Pagano – volume: 42 start-page: 83 year: 2010 end-page: 88 ident: bib28 article-title: Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice publication-title: Nat. Genet. contributor: fullname: Zhu – volume: 282 start-page: 2038 year: 2007 end-page: 2046 ident: bib22 article-title: Skp2 controls adipocyte proliferation during the development of obesity publication-title: J. Biol. Chem. contributor: fullname: Kasuga – volume: 416 start-page: 703 year: 2002 end-page: 709 ident: bib38 article-title: Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex publication-title: Nature contributor: fullname: Pagano – volume: 19 start-page: 2046 year: 2011 end-page: 2054 ident: bib1 article-title: Development of sulfonamide AKT PH domain inhibitors publication-title: Bioorg. Med. Chem. contributor: fullname: Mash – volume: 324 start-page: 1029 year: 2009 end-page: 1033 ident: bib25 article-title: Understanding the Warburg effect: the metabolic requirements of cell proliferation publication-title: Science contributor: fullname: Thompson – volume: 9 start-page: 126 year: 2008 ident: bib36 article-title: DOVIS: an implementation for high-throughput virtual screening using AutoDock publication-title: BMC Bioinformatics contributor: fullname: Reifman – volume: 111 start-page: 4690 year: 2008 end-page: 4699 ident: bib8 article-title: Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy publication-title: Blood contributor: fullname: Moutouh-de Parseval – volume: 11 start-page: 1177 year: 2003 end-page: 1188 ident: bib13 article-title: Skp2 regulates Myc protein stability and activity publication-title: Mol. Cell contributor: fullname: Tansey – volume: 17 start-page: 6983 year: 2009 end-page: 6992 ident: bib9 article-title: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain publication-title: Bioorg. Med. Chem. contributor: fullname: Zhang – volume: 19 start-page: 1515 year: 2012 end-page: 1524 ident: bib29 article-title: Specific small molecule inhibitors of Skp2-mediated p27 degradation publication-title: Chem. Biol. contributor: fullname: Cardozo – volume: 94 start-page: 344 year: 2003 end-page: 349 ident: bib32 article-title: Down-regulation of SKP2 induces apoptosis in lung-cancer cells publication-title: Cancer Sci. contributor: fullname: Inazawa – volume: 287 start-page: 245 year: 2012 end-page: 256 ident: bib30 article-title: 3-Formylchromone interacts with cysteine 38 in p65 protein and with cysteine 179 in IκBα kinase, leading to down-regulation of nuclear factor-κB (NF-κB)-regulated gene products and sensitization of tumor cells publication-title: J. Biol. Chem. contributor: fullname: Aggarwal – volume: 8 start-page: 438 year: 2008 end-page: 449 ident: bib11 article-title: Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer publication-title: Nat. Rev. Cancer contributor: fullname: Pagano – volume: 716 start-page: 23 year: 2011 end-page: 38 ident: bib33 article-title: Computer-aided drug discovery and development publication-title: Methods Mol. Biol. contributor: fullname: Zhang – volume: 5 start-page: 269 year: 2009 end-page: 279 ident: bib34 article-title: Development and evaluation of a new statistical model for structure-based high-throughput virtual screening publication-title: Int. J. Bioinform. Res. Appl. contributor: fullname: Du-Cuny – volume: 12 start-page: 457 year: 2010 end-page: 467 ident: bib4 article-title: Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis publication-title: Nat. Cell Biol. contributor: fullname: Huang – volume: 11 start-page: 420 year: 2009 end-page: 432 ident: bib16 article-title: Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB publication-title: Nat. Cell Biol. contributor: fullname: Nimer – volume: 408 start-page: 381 year: 2000 end-page: 386 ident: bib23 article-title: Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex publication-title: Nature contributor: fullname: Pavletich – volume: 464 start-page: 374 year: 2010 end-page: 379 ident: bib17 article-title: Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence publication-title: Nature contributor: fullname: Nakayama – volume: 278 start-page: 25752 year: 2003 end-page: 25757 ident: bib2 article-title: Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase publication-title: J. Biol. Chem. contributor: fullname: Hershko – volume: 16 start-page: 154 year: 2010 end-page: 163 ident: bib18 article-title: The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth publication-title: Clin. Cancer Res. contributor: fullname: Bachoo – volume: 19 start-page: 25 year: 2009 end-page: 31 ident: bib21 article-title: Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis publication-title: Semin. Cancer Biol. contributor: fullname: Hay – volume: 64 start-page: 3892 year: 2004 end-page: 3899 ident: bib10 article-title: Akt stimulates aerobic glycolysis in cancer cells publication-title: Cancer Res. contributor: fullname: Thompson – volume: 148 start-page: 259 year: 2012 end-page: 272 ident: bib37 article-title: Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis publication-title: Cell contributor: fullname: Nga – volume: 398 start-page: 125 year: 2005 end-page: 142 ident: bib15 article-title: High-level expression and purification of recombinant SCF ubiquitin ligases publication-title: Methods Enzymol. contributor: fullname: Zheng – volume: 7 start-page: 979 year: 2008 end-page: 987 ident: bib26 article-title: The genetics of the p53 pathway, apoptosis and cancer therapy publication-title: Nat. Rev. Drug Discov. contributor: fullname: Bond – volume: 458 start-page: 732 year: 2009 end-page: 736 ident: bib24 article-title: An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer publication-title: Nature contributor: fullname: Critchley – volume: 21 start-page: 97 year: 2007 end-page: 112 ident: bib35 article-title: Antitumor agents 252. Application of validated QSAR models to database mining: discovery of novel tylophorine derivatives as potential anticancer agents publication-title: J. Comput. Aided Mol. Des. contributor: fullname: Tropsha – volume: 20 start-page: 116 year: 2010 end-page: 124 ident: bib14 article-title: Cancer stem cells at the crossroads of current cancer therapy failures—radiation oncology perspective publication-title: Semin. Cancer Biol. contributor: fullname: Baumann – volume: 4 start-page: 211 year: 2008 end-page: 216 ident: bib20 article-title: Targeting cancer stem cells in cancer prevention and therapy publication-title: Stem Cell Rev. contributor: fullname: Srinivasan – volume: 6 start-page: 661 year: 2004 end-page: 672 ident: bib19 article-title: Skp2-mediated degradation of p27 regulates progression into mitosis publication-title: Dev. Cell contributor: fullname: Nakayama – volume: 112 start-page: 1415 year: 2008 end-page: 1424 ident: bib12 article-title: Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer publication-title: Cancer contributor: fullname: Hershko – volume: 89 start-page: 857 year: 2011 end-page: 867 ident: bib6 article-title: Novel ARF/p53-independent senescence pathways in cancer repression publication-title: J. Mol. Med. contributor: fullname: Lin – volume: 149 start-page: 1098 year: 2012 end-page: 1111 ident: bib7 article-title: The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis publication-title: Cell contributor: fullname: Shao – volume: 325 start-page: 1134 year: 2009 end-page: 1138 ident: bib31 article-title: The E3 ligase TRAF6 regulates Akt ubiquitination and activation publication-title: Science contributor: fullname: Lin – volume: 9 start-page: 126 year: 2008 ident: 10.1016/j.cell.2013.06.048_bib36 article-title: DOVIS: an implementation for high-throughput virtual screening using AutoDock publication-title: BMC Bioinformatics contributor: fullname: Zhang – volume: 19 start-page: 2046 year: 2011 ident: 10.1016/j.cell.2013.06.048_bib1 article-title: Development of sulfonamide AKT PH domain inhibitors publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2011.01.049 contributor: fullname: Ahad – volume: 282 start-page: 2038 year: 2007 ident: 10.1016/j.cell.2013.06.048_bib22 article-title: Skp2 controls adipocyte proliferation during the development of obesity publication-title: J. Biol. Chem. doi: 10.1074/jbc.M608144200 contributor: fullname: Sakai – volume: 464 start-page: 374 year: 2010 ident: 10.1016/j.cell.2013.06.048_bib17 article-title: Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence publication-title: Nature doi: 10.1038/nature08815 contributor: fullname: Lin – volume: 287 start-page: 245 year: 2012 ident: 10.1016/j.cell.2013.06.048_bib30 article-title: 3-Formylchromone interacts with cysteine 38 in p65 protein and with cysteine 179 in IκBα kinase, leading to down-regulation of nuclear factor-κB (NF-κB)-regulated gene products and sensitization of tumor cells publication-title: J. Biol. Chem. doi: 10.1074/jbc.M111.274613 contributor: fullname: Yadav – volume: 325 start-page: 1134 year: 2009 ident: 10.1016/j.cell.2013.06.048_bib31 article-title: The E3 ligase TRAF6 regulates Akt ubiquitination and activation publication-title: Science doi: 10.1126/science.1175065 contributor: fullname: Yang – volume: 11 start-page: 1189 year: 2003 ident: 10.1016/j.cell.2013.06.048_bib27 article-title: The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription publication-title: Mol. Cell doi: 10.1016/S1097-2765(03)00193-X contributor: fullname: von der Lehr – volume: 5 start-page: 269 year: 2009 ident: 10.1016/j.cell.2013.06.048_bib34 article-title: Development and evaluation of a new statistical model for structure-based high-throughput virtual screening publication-title: Int. J. Bioinform. Res. Appl. doi: 10.1504/IJBRA.2009.026419 contributor: fullname: Zhang – volume: 148 start-page: 259 year: 2012 ident: 10.1016/j.cell.2013.06.048_bib37 article-title: Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis publication-title: Cell doi: 10.1016/j.cell.2011.11.050 contributor: fullname: Zhang – volume: 10 start-page: 1001 year: 2010 ident: 10.1016/j.cell.2013.06.048_bib5 article-title: Regulation of Skp2 expression and activity and its role in cancer progression publication-title: ScientificWorldJournal doi: 10.1100/tsw.2010.89 contributor: fullname: Chan – volume: 408 start-page: 381 year: 2000 ident: 10.1016/j.cell.2013.06.048_bib23 article-title: Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex publication-title: Nature doi: 10.1038/35042620 contributor: fullname: Schulman – volume: 21 start-page: 97 year: 2007 ident: 10.1016/j.cell.2013.06.048_bib35 article-title: Antitumor agents 252. Application of validated QSAR models to database mining: discovery of novel tylophorine derivatives as potential anticancer agents publication-title: J. Comput. Aided Mol. Des. doi: 10.1007/s10822-007-9102-6 contributor: fullname: Zhang – volume: 8 start-page: 438 year: 2008 ident: 10.1016/j.cell.2013.06.048_bib11 article-title: Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer publication-title: Nat. Rev. Cancer doi: 10.1038/nrc2396 contributor: fullname: Frescas – volume: 12 start-page: 457 year: 2010 ident: 10.1016/j.cell.2013.06.048_bib4 article-title: Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis publication-title: Nat. Cell Biol. doi: 10.1038/ncb2047 contributor: fullname: Chan – volume: 111 start-page: 4690 year: 2008 ident: 10.1016/j.cell.2013.06.048_bib8 article-title: Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy publication-title: Blood doi: 10.1182/blood-2007-09-112904 contributor: fullname: Chen – volume: 324 start-page: 1029 year: 2009 ident: 10.1016/j.cell.2013.06.048_bib25 article-title: Understanding the Warburg effect: the metabolic requirements of cell proliferation publication-title: Science doi: 10.1126/science.1160809 contributor: fullname: Vander Heiden – volume: 11 start-page: 1177 year: 2003 ident: 10.1016/j.cell.2013.06.048_bib13 article-title: Skp2 regulates Myc protein stability and activity publication-title: Mol. Cell doi: 10.1016/S1097-2765(03)00173-4 contributor: fullname: Kim – volume: 458 start-page: 732 year: 2009 ident: 10.1016/j.cell.2013.06.048_bib24 article-title: An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer publication-title: Nature doi: 10.1038/nature07884 contributor: fullname: Soucy – volume: 38 start-page: W402 issue: Web Server issue year: 2010 ident: 10.1016/j.cell.2013.06.048_bib42 article-title: HotPoint: hot spot prediction server for protein interfaces publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkq323 contributor: fullname: Tuncbag – volume: 6 start-page: 661 year: 2004 ident: 10.1016/j.cell.2013.06.048_bib19 article-title: Skp2-mediated degradation of p27 regulates progression into mitosis publication-title: Dev. Cell doi: 10.1016/S1534-5807(04)00131-5 contributor: fullname: Nakayama – volume: 42 start-page: 83 year: 2010 ident: 10.1016/j.cell.2013.06.048_bib28 article-title: Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice publication-title: Nat. Genet. doi: 10.1038/ng.498 contributor: fullname: Wang – volume: 1 start-page: 193 year: 1999 ident: 10.1016/j.cell.2013.06.048_bib3 article-title: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 publication-title: Nat. Cell Biol. doi: 10.1038/12013 contributor: fullname: Carrano – volume: 11 start-page: 420 year: 2009 ident: 10.1016/j.cell.2013.06.048_bib16 article-title: Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB publication-title: Nat. Cell Biol. doi: 10.1038/ncb1849 contributor: fullname: Lin – volume: 19 start-page: 1515 year: 2012 ident: 10.1016/j.cell.2013.06.048_bib29 article-title: Specific small molecule inhibitors of Skp2-mediated p27 degradation publication-title: Chem. Biol. doi: 10.1016/j.chembiol.2012.09.015 contributor: fullname: Wu – volume: 149 start-page: 1098 year: 2012 ident: 10.1016/j.cell.2013.06.048_bib7 article-title: The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis publication-title: Cell doi: 10.1016/j.cell.2012.02.065 contributor: fullname: Chan – volume: 20 start-page: 9 year: 2005 ident: 10.1016/j.cell.2013.06.048_bib40 article-title: Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase publication-title: Mol. Cell doi: 10.1016/j.molcel.2005.09.003 contributor: fullname: Hao – volume: 4 start-page: 211 year: 2008 ident: 10.1016/j.cell.2013.06.048_bib20 article-title: Targeting cancer stem cells in cancer prevention and therapy publication-title: Stem Cell Rev. doi: 10.1007/s12015-008-9037-x contributor: fullname: Rajan – volume: 416 start-page: 703 year: 2002 ident: 10.1016/j.cell.2013.06.048_bib38 article-title: Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex publication-title: Nature doi: 10.1038/416703a contributor: fullname: Zheng – volume: 278 start-page: 25752 year: 2003 ident: 10.1016/j.cell.2013.06.048_bib2 article-title: Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase publication-title: J. Biol. Chem. doi: 10.1074/jbc.M301774200 contributor: fullname: Bornstein – volume: 89 start-page: 857 year: 2011 ident: 10.1016/j.cell.2013.06.048_bib6 article-title: Novel ARF/p53-independent senescence pathways in cancer repression publication-title: J. Mol. Med. doi: 10.1007/s00109-011-0766-y contributor: fullname: Chan – volume: 16 start-page: 154 year: 2010 ident: 10.1016/j.cell.2013.06.048_bib18 article-title: The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-2850 contributor: fullname: Marian – volume: 25 start-page: 621 year: 2009 ident: 10.1016/j.cell.2013.06.048_bib39 article-title: Fragment-based identification of druggable ‘hot spots’ of proteins using Fourier domain correlation techniques publication-title: Bioinformatics doi: 10.1093/bioinformatics/btp036 contributor: fullname: Brenke – volume: 7 start-page: 979 year: 2008 ident: 10.1016/j.cell.2013.06.048_bib26 article-title: The genetics of the p53 pathway, apoptosis and cancer therapy publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd2656 contributor: fullname: Vazquez – volume: 64 start-page: 3892 year: 2004 ident: 10.1016/j.cell.2013.06.048_bib10 article-title: Akt stimulates aerobic glycolysis in cancer cells publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-03-2904 contributor: fullname: Elstrom – volume: 19 start-page: 25 year: 2009 ident: 10.1016/j.cell.2013.06.048_bib21 article-title: Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2008.11.010 contributor: fullname: Robey – volume: 716 start-page: 23 year: 2011 ident: 10.1016/j.cell.2013.06.048_bib33 article-title: Computer-aided drug discovery and development publication-title: Methods Mol. Biol. doi: 10.1007/978-1-61779-012-6_2 contributor: fullname: Zhang – volume: 112 start-page: 1415 year: 2008 ident: 10.1016/j.cell.2013.06.048_bib12 article-title: Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer publication-title: Cancer doi: 10.1002/cncr.23317 contributor: fullname: Hershko – volume: 94 start-page: 344 year: 2003 ident: 10.1016/j.cell.2013.06.048_bib32 article-title: Down-regulation of SKP2 induces apoptosis in lung-cancer cells publication-title: Cancer Sci. doi: 10.1111/j.1349-7006.2003.tb01444.x contributor: fullname: Yokoi – volume: 51 start-page: 2352 year: 2011 ident: 10.1016/j.cell.2013.06.048_bib41 article-title: Accurate prediction of the bound form of the Akt pleckstrin homology domain using normal mode analysis to explore structural flexibility publication-title: J. Chem. Inf. Model. doi: 10.1021/ci2001742 contributor: fullname: Tran – volume: 398 start-page: 125 year: 2005 ident: 10.1016/j.cell.2013.06.048_bib15 article-title: High-level expression and purification of recombinant SCF ubiquitin ligases publication-title: Methods Enzymol. doi: 10.1016/S0076-6879(05)98012-9 contributor: fullname: Li – volume: 17 start-page: 6983 year: 2009 ident: 10.1016/j.cell.2013.06.048_bib9 article-title: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2009.08.022 contributor: fullname: Du-Cuny – volume: 20 start-page: 116 year: 2010 ident: 10.1016/j.cell.2013.06.048_bib14 article-title: Cancer stem cells at the crossroads of current cancer therapy failures—radiation oncology perspective publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2010.02.003 contributor: fullname: Koch |
SSID | ssj0008555 |
Score | 2.6081278 |
Snippet | Skp2 E3 ligase is overexpressed in numerous human cancers and plays a critical role in cell-cycle progression, senescence, metabolism, cancer progression, and... Skp2 E3 ligase is overexpressed in numerous human cancers and plays a critical role in cell cycle progression, senescence, metabolism, cancer progression and... |
SourceID | pubmedcentral proquest crossref pubmed fao elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 556 |
SubjectTerms | animal models Animals antineoplastic agents Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology cell cycle cell senescence cell viability cells Disease Models, Animal Drug Discovery Drug Screening Assays, Antitumor drug therapy Genes, p53 glycolysis Glycolysis - drug effects Humans ligases metastasis Mice Mice, Nude Models, Molecular Multienzyme Complexes - antagonists & inhibitors Multienzyme Complexes - chemistry Multienzyme Complexes - metabolism Neoplasm Transplantation neoplasms Neoplasms - drug therapy Neoplasms - enzymology Neoplasms - genetics Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - metabolism population S-Phase Kinase-Associated Proteins - antagonists & inhibitors S-Phase Kinase-Associated Proteins - chemistry S-Phase Kinase-Associated Proteins - metabolism screening senescence Small Molecule Libraries stem cells Structure-Activity Relationship Transplantation, Heterologous ubiquitin-protein ligase Ubiquitin-Protein Ligases - antagonists & inhibitors Ubiquitin-Protein Ligases - chemistry Ubiquitin-Protein Ligases - metabolism |
Title | Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression |
URI | https://dx.doi.org/10.1016/j.cell.2013.06.048 https://www.ncbi.nlm.nih.gov/pubmed/23911321 https://search.proquest.com/docview/1418148009 https://pubmed.ncbi.nlm.nih.gov/PMC3845452 |
Volume | 154 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB71ISQuiHfDozISNxQ1azuxc2wjVi2UUrEsWnGx7NgpAZFdttkD_56ZTbKwqOLAMQ9LTj77mxlr5huAlyEtJcmcxV7pMsb4q4q1z31cauEqKytpBRUKv7vITqfyzSyd7UAx1MJQWmXP_R2nr9m6v3PU_82jRV1TjW_OdaaIhdGPoBqufdIyx6W9f3zy6e35hpB1mnaNDHLc_Digr53p0rzofJwyvMRaxpPaAN1sn3YrO7_JC_07mfIP6zS-C3d6t5IddzO_BzuhuQ-3ukaTPx_A8vK3QjWhws4aKmjojmPZvGKTbwvOJsWYTV39Y1W3dcPO6yu0cOxDoM4eZXvNClogSzZpw3dW4PcwtHM13reNH55dUrZXp_TxEKbj1x-L07jvthCXUqVtjOBQVa4WmS2lc4lXnstSWY40pDAKHEnlQsUtT7TFOCi32vMqHWXoUzgbhBCPYK-ZN-EAGMcYEa1e5UuLnOASq3jIlFIj73nmRBLBq-Efm0UnqmGGbLOvhhAxhIihlDupI0gHGMzW0jDI-v8cd4CYGXuFbGmmE05aeuSyJFJE8GIA0uB2opG2CfPVNUZC6PJI9KLzCB53wG6myAVaBsFHEagtyDcvkFT39pOm_rKW7BZaUjP3J__5KU_hNl-34aDEw2ew1y5X4Tk6Q6077Bf7IeyezU7w6qKYvf_8C0M9CLU |
link.rule.ids | 230,314,780,784,885,3506,27569,27924,27925,45663,45874 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nj9MwELWWRYi9IL43fBqJG4o2tZ3YOUJE1UJ3taJbqTfLjp0loE1LNz3w75mJk0LRigPXJJaSPOfNTPTmDSFvfVoKtDmLnVRlDPVXFSuXu7hU3FZGVMJwbBQ-PcsmC_FpmS4PSDH0wqCssuf-wOkdW_dHTvq3ebKua-zxzZnKJLIw5BHYw3VbpEqigf50-WFHxypNwxiDHD59uLzvnAkiL_w7jvou3pl44hCgm6PTrcqsbspB_5ZS_hGbxvfJvT6ppO_DfT8gB755SO6EMZM_H5HN-W9_asSEThtsZwg_Y-mqovPva0bnxZgubP1jW7d1Q2f1JcQ3-sXjXI-yvaYFbo8Nnbf-ihbwPBSiXA3HTeOGc-eo9Qo-H4_JYvzxopjE_ayFuBQybWOABntyFc9MKaxNnHRMlNIwICEJNeBISOsrZliiDFRBuVGOVekog4zCGs85f0IOm1XjjwllUCFCzKtcaYARbGIk85mUcuQcyyxPIvJueMd6HSw19KA1-6YREY2IaBTcCRWRdIBB720MDZz_z3XHgJk2l8CVejFn6KSHCUsieETeDEBq-JhwpWn8ansNdRAkPAJy6DwiTwOwu1tkHOICZ6OIyD3IdxegUff-mab-2hl2cyVwlPuz_3yU1-Tu5OJ0pmfTs8_PyRFDVU0nqHlBDtvN1r-EtKi1r7pt_ws92QfB |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacological+Inactivation+of+Skp2+SCF+Ubiquitin+Ligase+Restricts+Cancer+Stem+Cell+Traits+and+Cancer+Progression&rft.jtitle=Cell&rft.au=Chan%2C+Chia-Hsin&rft.au=Morrow%2C+John%C2%A0Kenneth&rft.au=Li%2C+Chien-Feng&rft.au=Gao%2C+Yuan&rft.date=2013-08-01&rft.pub=Elsevier+Inc&rft.issn=0092-8674&rft.eissn=1097-4172&rft.volume=154&rft.issue=3&rft.spage=556&rft.epage=568&rft_id=info:doi/10.1016%2Fj.cell.2013.06.048&rft.externalDocID=US201600022043 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0092-8674&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0092-8674&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0092-8674&client=summon |